John Zajecka

10.7k total citations · 1 hit paper
91 papers, 6.0k citations indexed

About

John Zajecka is a scholar working on Pharmacology, Psychiatry and Mental health and Experimental and Cognitive Psychology. According to data from OpenAlex, John Zajecka has authored 91 papers receiving a total of 6.0k indexed citations (citations by other indexed papers that have themselves been cited), including 54 papers in Pharmacology, 44 papers in Psychiatry and Mental health and 13 papers in Experimental and Cognitive Psychology. Recurrent topics in John Zajecka's work include Treatment of Major Depression (54 papers), Electroconvulsive Therapy Studies (20 papers) and Bipolar Disorder and Treatment (16 papers). John Zajecka is often cited by papers focused on Treatment of Major Depression (54 papers), Electroconvulsive Therapy Studies (20 papers) and Bipolar Disorder and Treatment (16 papers). John Zajecka collaborates with scholars based in United States, Canada and Germany. John Zajecka's co-authors include Robert M. A. Hirschfeld, Susan L. McElroy, Roy H. Perlis, Joseph R. Calabrese, Lydia Lewis, Laurie M. Flynn, Janet B. W. Williams, James M. Russell, Robert M. Post and Robert L. Spitzer and has published in prestigious journals such as American Journal of Psychiatry, Biological Psychiatry and Neuropsychopharmacology.

In The Last Decade

John Zajecka

85 papers receiving 5.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Development and Validation of a Screening Instrument for Bipolar Spectrum Disorder: The Mood Disorder Questionnaire

2000 1.1k citations Robert M. A. Hirschfeld, John Zajecka et al. American Journal of Psychiatry profile →

Peers

Countries citing papers authored by John Zajecka

Since Specialization

Citations

This map shows the geographic impact of John Zajecka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Zajecka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Zajecka more than expected).

Fields of papers citing papers by John Zajecka

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Zajecka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Zajecka. The network helps show where John Zajecka may publish in the future.

Co-authorship network of co-authors of John Zajecka

This figure shows the co-authorship network connecting the top 25 collaborators of John Zajecka. A scholar is included among the top collaborators of John Zajecka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Zajecka. John Zajecka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	<p>Buprenorphine/samidorphan combination for the adjunctive treatment of major depressive disorder: results of a phase III clinical trial (FORWARD-3)</p> 2019 ·Neuropsychiatric Disease and Treatment ·John Zajecka, Arielle D. Stanford, Aslı Memişoğlu, William Martin, Sanjeev Pathak	23
2	Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study 2016 ·Neuropsychopharmacology ·Gerard Sanacora, Michael R. Johnson, Arif Khan, Sarah Atkinson, (unknown), Juan Schronen, (unknown), John Zajecka, (unknown), (unknown), Joel A. Posener, Khanh Bui, Michael C. Quirk, Timothy M. Piser, Sanjay J. Mathew, Sanjeev Pathak	89
3	Long-Term Efficacy, Safety, and Tolerability of <span style="font-variant:small-caps; "> l</span>-Methylfolate Calcium 15 mg as Adjunctive Therapy With Selective Serotonin Reuptake Inhibitors 2016 ·The Journal of Clinical Psychiatry ·John Zajecka, Maurizio Fava, Richard C. Shelton, (unknown), (unknown), George I. Papakostas	20
4	The pro-inflammatory profile of depressed patients is (partly) related to obesity 2015 ·Journal of Psychiatric Research ·Richard C. Shelton, (unknown), (unknown), John Zajecka, Maurizio Fava, George I. Papakostas	50
5	Association of Obesity and Inflammatory Marker Levels on Treatment Outcome 2015 ·The Journal of Clinical Psychiatry ·Richard C. Shelton, Michael Pencina, (unknown), Juan Ruiz, Maurizio Fava, John Zajecka, George I. Papakostas	46
6	Residual Symptoms and Relapse 2013 ·The Journal of Clinical Psychiatry ·John Zajecka	31
7	l -Methylfolate as Adjunctive Therapy for SSRI-Resistant Major Depression: Results of Two Randomized, Double-Blind, Parallel-Sequential Trials 2012 ·American Journal of Psychiatry ·George I. Papakostas, Richard C. Shelton, John Zajecka, Bijan Etemad, Karl Rickels, Alisabet Clain, Lee Baer, Elizabeth D. Dalton, (unknown), David Schoenfeld, Michael Pencina, Allison Meisner, Teodoro Bottiglieri, Erik Nelson, David Mischoulon, Jonathan E. Alpert, James G. Barbee, Sidney Zisook, Maurizio Fava	182
8	Psychosocial outcomes in patients with recurrent major depressive disorder during 2 years of maintenance treatment with venlafaxine extended release 2010 ·Journal of Affective Disorders ·Madhukar H. Trivedi, David L. Dünner, Susan G. Kornstein, Michael E. Thase, John Zajecka, Anthony J. Rothschild, Edward S. Friedman, Richard C. Shelton, Martin B. Keller, James H. Kocsis, Alan J. Gelenberg	34
9	Augmentation strategies to increase antidepressant tolerability. 2007 ·PubMed ·John Zajecka	8
10	Prevention of Recurrent Episodes of Depression With Venlafaxine ER in a 1-Year Maintenance Phase From the PREVENT Study 2007 ·The Journal of Clinical Psychiatry ·James H. Kocsis, Michael E. Thase, Madhukar H. Trivedi, Richard C. Shelton, Susan G. Kornstein, Charles B. Nemeroff, Edward S. Friedman, Alan J. Gelenberg, David L. Dünner, Robert M. A. Hirschfeld, Anthony J. Rothschild, James M. Ferguson, Alan F. Schatzberg, John Zajecka, Ronald Pedersen, Bing Chun Yan, Saeed Ahmed, Jeff Musgnung, Philip T. Ninan, Martín Keller	46
11	Paroxetine for prevention of depressive symptoms induced by interferon‐alpha and ribavirin for hepatitis C 2007 ·Alimentary Pharmacology & Therapeutics ·Charles L. Raison, Bobbi J. Woolwine, (unknown), Andrey Borisov, (unknown), Jeffrey P. Staab, John Zajecka, (unknown), Max Henderson, John F. Reinus, Dwight L. Evans, Gregory M. Asnis, Andrew H. Miller	114
12	A Randomized, Double-Blind, Active-Control Study of Sertraline Versus Venlafaxine XR in Major Depressive Disorder 2006 ·The Journal of Clinical Psychiatry ·Richard C. Shelton, Kirsten Haman, Mark Hyman Rapaport, Ari Kiev, Ward T. Smith, Robert M. A. Hirschfeld, R. Bruce Lydiard, John Zajecka, David L. Dünner	39
13	Vagus Nerve Stimulation for Treatment-Resistant\nDepression: A Randomized, Controlled Acute\nPhase Trial 2005 ·Insecta mundi ·A. John Rush, Lauren B. Marangell, Harold A. Sackeïm, Mark S. George, Stephen K. Brannan, Sonia M. Davis, Robert H. Howland, Mitchel A. Kling, Barry R. Rittberg, W. J. Burke, Mark Hyman Rapaport, John Zajecka, Andrew A. Nierenberg, Mustafa M. Husain, David Ginsberg, R.G. Cooke	416
14	Vagus Nerve Stimulation for Treatment-Resistant Depression: A Randomized, Controlled Acute Phase Trial 2005 ·Biological Psychiatry ·A. John Rush, Lauren B. Marangell, Harold A. Sackeïm, Mark S. George, Stephen K. Brannan, Sonia M. Davis, Robert H. Howland, Mitchel A. Kling, Barry R. Rittberg, W. J. Burke, Mark Hyman Rapaport, John Zajecka, Andrew A. Nierenberg, Mustafa M. Husain, David Ginsberg, R.G. Cooke	18
15	The Modified Rush Sexual Inventory: Preliminary psychometric findings 2005 ·Psychiatry Research ·Deepa Rao, John Zajecka, (unknown)	8
16	SNRIs in the management of acute major depressive disorder. 2004 ·PubMed ·John Zajecka, (unknown)	23
17	Safety of Abrupt Discontinuation of Fluoxetine 1998 ·Journal of Clinical Psychopharmacology ·John Zajecka, Jan Fawcett, Jay D. Amsterdam, Frederic M. Quitkin, Frederick W. Reimherr, J F Rosenbaum, David Michelson, Charles M. Beasley	58
18	Optimal Length of Continuation Therapy in Depression: A Prospective Assessment During Long-Term Fluoxetine Treatment 1998 ·American Journal of Psychiatry ·Frederick W. Reimherr, Jay D. Amsterdam, Frederic M. Quitkin, Jerrold F. Rosenbaum, Maurizio Fava, John Zajecka, Charles M. Beasley, David Michelson, Paul Roback, Karen Sundell	151
19	Serotonin Reuptake Inhibitor Discontinuation Syndrome: A Hypothetical Definition 1997 ·The Journal of Clinical Psychiatry ·Alan F. Schatzberg, Peter Haddad, (unknown), Michel Lejoyeux, Jerrold F. Rosenbaum, Andrew Young, John Zajecka	62
20	Possible Biological Mechanisms of the Serotonin Reuptake Inhibitor Discontinuation Syndrome 1997 ·The Journal of Clinical Psychiatry ·Alan F. Schatzberg, Peter Haddad, (unknown), Michel Lejoyeux, Jerrold F. Rosenbaum, Andrew Young, John Zajecka	52

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact